Adc Therapeutics Sa · NYSE:ADCT
Adc Therapeutics Sa — Q3 2022 Earnings Presentation
11 slides from Adc Therapeutics Sa's earnings presentation, Nov 8, 2022
Slide 1: 3Q 2022 Earnings Call
3Q 2022 Earnings Call November 8, 2022
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we” or “us”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a reco
Slide 3: Agenda
Agenda 01 Ameet Mallik Introduction & Chief Executive Officer Commercial Highlights 02 Joseph Camardo Chief Medical Officer Clinical Highlights 03 Jenn Creel Chief Financial Officer Financial Update 3
Slide 4: Recent Highlights
Recent Highlights ZYNLONTA® • Net sales: $21.3M in 3Q 2022, +23% vs. 2Q 2022, driven by new initiatives started in 2Q & 3Q (loncastuximab • Encouraging safety run-in data from Phase 3 LOTIS-5 trial presented at SOHO congress in September tesirine-lpyl) • Positive opinion from CHMP for ZYNLONTA in Eu
Slide 5: ZYNLONTA: 3Q 2022 Net sales of $21.3 million
ZYNLONTA: 3Q 2022 Net sales of $21.3 million Targeted initiatives accelerating launch § Enhanced promotional materials and launched new regional Healthcare marketing capability professionals § Increased face-to-face interactions to build awareness, familiarity, trial and adoption Community § Rapid g
Slide 6: Focused ZYNLONTA Strategy To Maximize Potential
Focused ZYNLONTA Strategy To Maximize Potential LOTIS-7 Novel combinations § Phase 1 trial of ZYNLONTA in multiple NHL novel combinations § Initiated in June 2022, enrollment ongoing LOTIS-9 1L DLBCL unfit/frail § Phase 2 trial in combination with rituximab § Initiated in July 2022, enrollment ongoi
Slide 7: Cami Program Updates
Cami Program Updates Hodgkin lymphoma (HL) Solid tumors § Regulatory landscape is evolving more dramatically § Study employed unique approach to enhance than previously anticipated with regards to immune activation by targeting specific intratumor T- accelerated approvals cells, rather than a direct
Slide 8: Robust Pipeline
Robust Pipeline § Novel, first-in-class asset targeting solid tumors including platinum-resistant ovarian cancer, fallopian ADCT-901 tube cancer, prostate cancer, cholangiocarcinoma, RCC and TNBC Targeting KAAG1 § Dose escalation in Phase 1 trial proceeding; safety and efficacy data anticipated in 2
Slide 9: 3Q and YTD 2022 Financial Update (in $ millions)
3Q and YTD 2022 Financial Update (in $ millions) Cash runway expected into early 2025 based on current business plan and expected milestones from Sobi and Healthcare Royalty Partners Balance Sheet September 30, 2022 June 30, 2022 Cash and cash equivalents $380.9 $376.8 Statement of Operations 3Q 202
Slide 10: Development Milestones
Development Milestones Hematology Programs ZYNLONTA: q 1H 2022: Initiate randomized portion of the LOTIS-5 confirmatory trial in combination with rituximab q 1H 2022: Initiate LOTS-7 trial in multiple combinations in NHL q 2H 2022: Initiate LOTIS-9 trial of ZYNLONTA + rituximab in 1L unfit/ frail DL
Slide 11: 3Q 2022 Earnings Call
3Q 2022 Earnings Call THERAPEUTICS Innovating Science. Inspiring Hope.